Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Marinus Pharma CS (NQ: MRNS )

6.350 -0.150 (-2.31%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 269,816
Open 6.580
Bid (Size) 6.110 (1)
Ask (Size) 6.720 (1)
Prev. Close 6.500
Today's Range 6.185 - 6.690
52wk Range 3.465 - 12.37
Shares Outstanding 37,196,644
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Marinus Pharmaceuticals Appoints Christine Silverstein to its Board of Directors
From Marinus Pharmaceuticals
Via Business Wire
Noting Strong Progress On Marinus Pharma's Lead Drug Ganaxolone, Analyst Initiates With 300% Upside
 
Via Benzinga

Performance

YTD
+49.41%
+49.41%
1 Month
+49.41%
+49.41%
3 Month
+9.86%
+9.86%
6 Month
+20.27%
+20.27%
1 Year
-38.23%
-38.23%

More News

Read More
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharma, Tenacia Biotech Ink Ganaxolone Agreement In China
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2023
Via Benzinga
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 ZTALMY® Net Product Revenue and Provides Business Update
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Presentations and Investor Event at American Epilepsy Society 2022 Annual Meeting
From Marinus Pharmaceuticals
Via Business Wire
Week In Review: Fosun Signs $840 Million Deal For US Rights To Henlius' PD-1
Via Talk Markets
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Appoints CEO Scott Braunstein, M.D., as Chairman of the Board
From Marinus Pharmaceuticals, Inc.
Via Business Wire
Marinus Pharmaceuticals Announces Collaboration with Tenacia Biotechnology for Ganaxolone Development and Commercialization in China
From Marinus Pharmaceuticals
Via Business Wire
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Via Benzinga
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Perrigo, Tripadvisor, Lyft, And Some Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Marinus Pharmaceuticals Announces Pricing of $60 Million Public Offering
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Proposed Public Offering
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces $32.5 Million Revenue Interest Financing Agreement with Sagard Healthcare Partners
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 8, 2022
From Marinus Pharmaceuticals
Via Business Wire
7 Sizzling Stocks That Are Oblivious to the Manic Market
Via InvestorPlace
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Multiple Presentations at Upcoming Medical Meetings
From Marinus Pharmaceuticals
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.